Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Gamida Cell Ltd is a biotechnology business based in the US. Gamida Cell shares (GMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Gamida Cell employs 110 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$4.04|
|52-week range||$3.88 - $12.47|
|50-day moving average||$4.78|
|200-day moving average||$6.45|
|Wall St. target price||$19.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.58|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||-0.98%|
|1 month (2021-08-25)||-16.01%|
|3 months (2021-06-25)||-38.41%|
|6 months (2021-03-26)||-48.67%|
|1 year (2020-09-25)||-4.94%|
|2 years (2019-09-25)||-13.86%|
|3 years (2018-09-22)||N/A|
|5 years (2016-09-22)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-32.85%|
|Return on equity TTM||-124.61%|
|Market capitalisation||$241.9 million|
TTM: trailing 12 months
There are currently 1.6 million Gamida Cell shares held short by investors – that's known as Gamida Cell's "short interest". This figure is 4.5% down from 1.7 million last month.
There are a few different ways that this level of interest in shorting Gamida Cell shares can be evaluated.
Gamida Cell's "short interest ratio" (SIR) is the quantity of Gamida Cell shares currently shorted divided by the average quantity of Gamida Cell shares traded daily (recently around 803314.64646465). Gamida Cell's SIR currently stands at 1.98. In other words for every 100,000 Gamida Cell shares traded daily on the market, roughly 1980 shares are currently held short.
However Gamida Cell's short interest can also be evaluated against the total number of Gamida Cell shares, or, against the total number of tradable Gamida Cell shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gamida Cell's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Gamida Cell shares in existence, roughly 30 shares are currently held short) or 0.0358% of the tradable shares (for every 100,000 tradable Gamida Cell shares, roughly 36 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Gamida Cell.
Find out more about how you can short Gamida Cell stock.
We're not expecting Gamida Cell to pay a dividend over the next 12 months.
Over the last 12 months, Gamida Cell's shares have ranged in value from as little as $3.88 up to $12.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gamida Cell's is 1.8758. This would suggest that Gamida Cell's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Gamida Cell Ltd. , a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel. .
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.